Evidence map›Paper›PMID 42675216›Full record

ArticleNature cancer2026

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial.

Jun Gong, Hayato Muranaka, So Yung Choi, Mourad Tighiouart, Shrikant Bhute, Ezinne R Aja, Jonathan P Jacobs, Aleksandr Stotland, Jennifer Van Eyk, Omer H M Elmadbouh and 12 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jun GongDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. jun.gong@csmc.edu.ORCID http://orcid.org/0000-0001-8713-1406
Hayato MuranakaDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
So Yung ChoiBiostatistics Shared Resource, Cedars-Sinai Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mourad TighiouartBiostatistics Shared Resource, Cedars-Sinai Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8021-5690
Shrikant BhuteThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Ezinne R AjaThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Jonathan P JacobsThe Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-4698-0254
Aleksandr StotlandAdvanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jennifer Van EykAdvanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-9050-148X
Omer H M ElmadbouhDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6912-1594
Mouad EdderkaouiDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2549-8242
Sunao TanakaDepartment of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Hideki FuruyaDepartment of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-9536-8662
Arsen OsipovDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jeremy LorberDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sandrine BilletDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alexzandra MorrisDepartment of Molecular and Medical Pharmacology, Metabolomics Center, University of California, Los Angeles, CA, USA.
Johanna Ten Hoeve-ScottDepartment of Molecular and Medical Pharmacology, Metabolomics Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0226-749X
Thomas GraeberDepartment of Molecular and Medical Pharmacology, Metabolomics Center, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8574-9181
Stephen J PandolDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0818-6017
Andrew HendifarDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Neil A BhowmickDepartment of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. neil.bhowmick@csmc.edu.ORCID http://orcid.org/0000-0001-8747-5989

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The paradoxical roles of beta hydroxy butyrate in the liver pro-metastatic nicheP01CA233452 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BHOWMICK, NEIL A., LU, SHELLY CHI-LOO · 2020 to 2024
$9.5M
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical TrialsU01CA232859 · NCI · CEDARS-SINAI MEDICAL CENTER · PI GANZ, PATRICIA A., TIGHIOUART, MOURAD · 2018 to 2023
$3.7M
NCATS NIH HHS UL1 TR001881NCI NIH HHS P01 CA233452NCI NIH HHS U01 CA232859U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA232859-01U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA233452U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) UL1 TR001881-01
6 · The paper itself

Abstract

Exogenous L-glutamine has preclinical antitumor activity although formal clinical translation has not been attempted. We conducted a single-arm phase 1 trial to assess the safety and preliminary efficacy of clinical-grade, US Food and Drug Administration-approved L-glutamine therapy with gemcitabine and nab-paclitaxel (GA) in participants with treatment-naive, advanced pancreatic cancer (n = 16). The primary endpoint was to determine the recommended phase 2 dose (RP2D) by adaptive Bayesian design across standard doses of GA and a dose range of 0.1-0.3 g kg

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalDeoxycytidineGlutaminePaclitaxelPancreatic NeoplasmsAdultAgedAlbuminsFemaleGemcitabineHumansMaleMiddle Aged130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabineGlutaminePaclitaxel

Identifiers

PMID42675216
PMCPMC13600916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.